PHASE-II STUDY OF RECOMBINANT ALPHA-INTERFERON (RIFN-ALPHA) AND CONTINUOUS-INFUSION 5-FLUOROURACIL IN METASTATIC BREAST-CANCER

Twenty-six patients with metastatic breast cancer were offered a phase IT combination of recombinant a-interferon and continuous-infusion 5- fluorouracil (5-FU). 5-FU was administered at 750 mg/m(2) daily for 5 days as a continuous infusion acid recombinant interferon at 5 million U/m(2) subcutaneously days 1, 3, and 5 of each course. The courses we re repeated every 14 days. Despite moderate nonmyelosuppressive toxici ty, only two (8%) partial remissions were observed. In this schedule, the addition of recombinant alpha-interferon to conventional continuou s-infusion 5-FU resulted in a response rate of 8%.